FDA approves pediatric indication for Norditropin

Article

The FDA has approved Novo Nordisk's Norditropin for the treatment of short stature in children who are small for gestational age (SGA) with no catch-up growth by age 2 to 4.

The FDA has approved Novo Nordisk's Norditropin for the treatment of short stature in children who are small for gestational age (SGA) with no catch-up growth by age 2 to 4.

The approval is based on data from a 13-year clinical trial of children with SGA. Results from the study showed that 63% of children who reached adult height were in the normal range of their peers.

Nortitropin (somatropin [rDNA origin] injection) is indicated for the treatment of children with short stature associated with Noonan syndrome or Turner Syndrome, treatment of children with growth failure due to inadequate secretion of endogenous growth hormone, and treatment of short stature in children born SGA with no catch-up growth by age 2, according to manufacturer Novo Nordisk.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
© 2025 MJH Life Sciences

All rights reserved.